CareView Communications Inc

NOTE1 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Interim Financial Statements

The accompanying unaudited interim Condensed Consolidated Financial Statements of CareView Communications, Inc. (“CareView”, the “Company”, “we”, “us” or “our”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form10-Q. Accordingly, they donot include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (the “SEC”). The balance sheet at* December 31, 2025has been derived from the audited Consolidated Financial Statements at that date but doesnot* include all of the information and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Results of operations for interim periods arenot necessarily indicative of results for the full year. The accompanying unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and related notes included in our Annual Report on Form10-K for the year ended* December 31, 2025as filed with the SEC on March 30, 2026.*

Revenue Recognition

We recognize revenue in accordance with Accounting Standards Codification (“ASC”) Topic606 (“ASC606”). For our subscription service contracts, we have employed the practical expedient discussed in ASC606-10-55-18 related to invoicing as we have the right to consideration from our customers in the amount that corresponds directly with the value to the customer of our performance completed to date and therefore, we recognize revenue upon invoicing as further discussed below.

In accordance with ASC606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC606 include afive-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation. For those customers for which we are required to collect sales taxes, we record such sales taxes on a net basis which hasno effect on the amount of revenue or expenses recognized as the sales taxes are a flow through to the taxing authority.

We enter into contracts with customers that* mayprovide multiple combinations of our products, software solutions, and other related services, which are generally capable of being distinct and accounted for as separate performance obligations. Performance obligations that arenot* distinct at contract inception are combined.

Customer contract fulfillment typically involves multiple procurement promises, which* may*include various equipment, software subscription, project-related installation and training services, and support. We allocate the transaction price to each performance obligation based on estimated relative standalone selling price. Revenue is then recognized for each performance obligation upon transferring control of the hardware, software, and services to the customer and in an amount that reflects the consideration we expect to receive and the estimated benefit the customer receives over the term of the contract.

Generally, we recognize revenue under each of our performance obligations as follows:

The Company earns sales-based contract revenue from services rendered under specific agreements, which hinge on athird-party reseller who possesses the exclusive authority to engage directly with veteran-owned hospitals. Evaluating the Company’s role in these contracts necessitates assessing whether it functions as the principal or agent, a determination that involves analyzing the extent of control the Company wields over the contracts.

7

Following its assessment, the Company reports revenue from services provided under such contracts on a gross basis. This decision is justified by the Company's primary responsibility to fulfill the contractual obligations, including delivery and installation of equipment and software, training, and its control over other services within the contract period. Furthermore, the Company directly sets the contract price with its customers based on the services outlined in the statement of work. As the Company is responsible for fulfilling this promise and maintains control, the Company is acting as the principal.

Disaggregation of Revenue

The following presents net revenues disaggregated by our business models:

Contract Liabilities

Our sales-based contract payment arrangements with our customers typically include an initial equipment payment due upon signing of the contract and subsequent payments when certain performance obligations are completed. Customer payments received in advance of satisfaction of related performance obligations are deferred as contract liabilities. These amounts are recorded as “deferred revenue” in our Condensed Consolidated Balance Sheets and recognized into revenues as either a point in time or over time.

During thethree andsix months ended* June 30, 2026and2025*, sales-based deferred contract liability recognized as revenue totaled $1,775,100 and $2,935,173 for2026, and $1,341,128 and $2,472,381 for2025, respectively. The table below details the sales-based contract liability activity during thethree andsix months ended* June 30, 2026and2025*.

8

As of* June 30, 2026*, the aggregate amount of deferred revenue from subscription-based contracts and sales-based contracts allocated to performance obligations that are unsatisfied or partially satisfied is $2,940,057 and will be recognized into revenue over time as follows:

We defer and capitalize all costs associated with the installation of the CareView System into a healthcare facility until the CareView System is fully operational and accepted by the healthcare facility. Installation costs are specifically identifiable based on the amounts we are charged fromthird party installers or directly identifiable internal labor hours incurred for each installation. Upon acceptance, the associated costs are expensed on a straight-line basis over the life of the contract with the healthcare facility. These costs are included in network operations on the accompanying Condensed Consolidated Statements of Operations.

The table below details the activity in these deferred installation costs during the periods ended* June 30, 2026and2025*, included in other assets in the accompanying unaudited Condensed Consolidated Balance Sheets.

Significant Judgements When Applying Topic606

Contracts with our customers are typically structured similarly and include various combinations of our products, software solutions, and related services. Determining whether the various contract promises are considered distinct performance obligations that should be accounted for separately versus together* may*require significant judgment.

The contract transaction price is allocated to distinct performance obligations using the estimated standalone selling price. We determine the standalone selling price through maximizing observable inputs such as standalone sales, competitor standalone sales, or substantive renewal prices charged to customers when they exist. In instances where the standalone selling price isnot observable, we utilize an estimate of standalone selling price. Such estimates are derived from various methods that include cost plus margin, and historical pricing practices. Judgment* may*be required to determine standalone selling prices for each performance obligation and whether it depicts the amount we expect to receive in exchange for the related good or service.

Contract modifications occur when we and our customers agree to modify existing customer contracts to change the scope or price (or both) of the contract or when a customer terminates some, or all, of the existing services provided by us. When a contract modification occurs, it requires us to exercise judgment to determine if the modification should be accounted for as a separate contract, the termination of the original contract and creation of a new contract, a cumulative catch-up adjustment to the original contract, or a combination.

Contracts with our customers include a limited warranty on our products covering materials, workmanship, or design for the duration of the contract. We donot offer paid additional extended or lifetime warranty packages. We determined that limited warranty in our contract isnot a distinct performance obligation. We donot believe our estimates of warranty costs to be significant to our determination of revenue recognition, and therefore, didnot reserve for warranty costs.

Leases

The Company has an operating lease primarily consisting of office space with a remaining lease term of54 months. At the lease commencement date, an operating lease liability and related operating lease asset are recognized. The operating lease liabilities are calculated using the present value of lease payments. The discount rate used is either the rate implicit in the lease, when known, or our estimated incremental borrowing rate. Operating lease assets are valued based on the initial operating lease liabilities plus any prepaid rent and direct costs from executing the leases.

Earnings (Loss) Per Share

We calculate earnings per share (“EPS”) in accordance with GAAP, which requires the computation and disclosure oftwo EPS amounts, basic and diluted. Basic EPS is computed based on the weighted average number of common shares outstanding during the period. Diluted EPS is computed based on the weighted average number of common shares outstanding plus all potentially dilutive common shares outstanding during the period under the treasury stock method. Such potential dilutive common shares consist of stock options, and warrants to purchase our Common Stock (the “Warrants”). Potential common shares totaling 66,731,835 and 67,206,835 on* June 30, 2026and2025*, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to our reported net loss. For2026, the 66,731,835 potential common shares consist of 65,481,835 stock options and 1,250,000 warrants, compared to 67,206,835 potential common shares in2025, which consisted of 65,956,835 stock options and 1,250,000 warrants.

9

Recently Adopted Accounting Pronouncements

In* December 2023,the FASB issued ASU2023*-09, Income Taxes (Topic740): Improvements to Income Tax Disclosures. This update will improve the transparency and usefulness of income tax disclosures. Investors, lenders, and creditors have indicated that current disclosures donot provide enough detailed information to assess how a company's operations, tax risks, and planning affect its tax rate and future cash flows. The requirements take effect for public business entities for fiscal years beginning after* December 15, 2024.The Company adopted this guidance on January 1, 2025,on a prospective basis. The adoption enhanced the Company’s income tax disclosures by increasing the level of detail and transparency but didnot* affect the Company’s financial position, results of operations, or cash flows.

In* November 2024,the FASB issued ASUNo.* 2024-04, “Debt with Conversion and Other Options (Subtopic470-20): Induced Conversions of Convertible Debt Instruments,” which clarifies the criteria for determining when a settlement of convertible debt should be accounted for as an induced conversion. The guidance applies only to conversions involving the full issuance of equity securities as originally specified in the debt terms and includes additional clarifications to aid in application. The amendments in this update are effective for all entities for annual reporting periods beginning after* December 15, 2025,and interim reporting periods within those annual reporting periods. The Company adopted this standard on January 1, 2026.The adoption of this guidance didnot* have a material impact on the Company’s Condensed Consolidated Financial Statements because the Company hadno outstanding convertible debt instruments upon adoption.

In* July 2025,the FASB issued ASU2025*-05, "Financial Instruments—Credit Losses (Topic326): Measurement of Credit Losses for Accounts Receivable and Contract Assets," which amends how entities estimate expected credit losses for current accounts receivable and current contract assets arising from revenue contracts under ASC606. The amendments simplify the measurement of expected credit losses for current accounts receivable and current contract assets by permitting entities to assume that current conditions as of the balance sheet date persist throughout the remaining contractual term of those assets, thereby reducing the need for complex forecasting. The amendments are effective for all entities for annual reporting periods beginning after* December 15, 2025,and interim periods within those annual reporting periods. The Company adopted this guidance on January 1, 2026.The adoption didnot* have a material impact on the Company's Condensed Consolidated Financial Statements.

There wasno impact on our Condensed Consolidated Financial Statements from recently adopted accounting standards.

Recently Issued Accounting Pronouncements

In* October 2023,the FASB issued ASUNo.* 2023-06, which incorporates14 of the27 SEC disclosures identified in SEC ReleaseNo. 33-10532 (issued* August 17, 2018).This ASU updates disclosure and presentation requirements across various Codification Topics and applies to all entities within the scope of those Topics, unless specified otherwise. The amendments are to be applied prospectively. For public business entities, each amendment becomes effective when the related SEC disclosure is removed from Regulation S-X or S-K; early adoption isnot* permitted. The Company is currently evaluating ASUNo. 2023-06 and doesnot expect it to impact its Condensed Consolidated Financial Statements.

In* November 2024,the FASB issued ASU2024*-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic220-40). This update enhances disclosures about public business entity’s expenses, responding to investor requests for more detailed information on components such as inventory purchases, employee compensation, depreciation, amortization, and depletion within commonly presented expense captions (e.g., cost of sales, SG&A, and R&D). These amendments are expected to provide investors with a clearer understanding of an entity’s expenses, helping them assess performance, forecast future expenses, and evaluate cash flow prospects. The effective date for these amendments, as clarified by ASU2025-01, is for annual reporting periods beginning after* December 15, 2026,and interim reporting periods within annual reporting periods beginning after December 15, 2027.*The standard can be applied either prospectively or retrospectively. We are currently assessing adoption timing and the effect that the updated standard will have on our financial statement disclosures.

In* September 2025,the FASB issued ASU2025*-06, "Intangibles—Goodwill and Other—Internal-Use Software (Subtopic350-40): Targeted Improvements to the Accounting for Internal-Use Software." The update eliminates all references to "development stages", so entities areno longer required to wait for a specific application development stage before capitalizing costs. Thetwo key criteria for when capitalization of internal-use software costs* maybegin are when Management has authorized and committed to funding the software project, and it is probable that the project will be completed and the software will be used to perform the intended function. The amendments are effective for all entities for annual reporting periods beginning after December 15, 2027,*and interim reporting periods within those annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. Management is currently assessing the potential effects on our financial statements and considering the possibility of early adoption.

There have beenno material changes to our significant accounting policies as summarized in NOTE1 of our Condensed Consolidated Financial Statements for the period ended* June**30,* 2026. We donot expect the adoption of recently issued accounting standards to have a material effect on our accompanying Condensed Consolidated Financial Statements.

NOTE2 – GOING CONCERN, LIQUIDITY AND MANAGEMENT’S PLANS

Accounting standards require management to evaluate our ability to continue as a going concern for a period ofone year after the issuance of these financial statements (“evaluation period”). In evaluating the Company’s ability to continue as a going concern, management considers the conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern for a period oftwelve months after the Company issues its financial statements. At thesix months ended* June 30, 2026*, management considered the Company’s current financial condition and liquidity sources, including current funds available, forecasted future cash flows, and the Company’s conditional and unconditional obligations due within12 months of the date these financial statements are issued.

The Company is subject to risks like those of healthcare technology companies whereby revenues are generated based on both sales-based and subscription-based models, which assume dependence on key individuals, uncertainty of product development, generation of revenues, positive cash flow, dependence on outside sources of capital, risks associated with research, development, and successful testing of its products, successful protection of intellectual property, ability to maintain and grow its customer base, and susceptibility to infringement on the proprietary rights of others. The Company’s net losses and working capital deficit raise substantial doubt about the Company’s ability to continue as a going concern. The attainment of profitable operations is dependent on future events, including obtaining adequate financing to fulfill the Company’s growth and operating activities and generating a level of revenue adequate to support the Company’s cost structure.

10

As of* June 30, 2026*, the Company had a working capital deficit of $44,287,693. The Company’s net losses, and working capital deficit raise substantial doubt about the Company’s ability to continue as a going concern. Management has evaluated the significance of the conditions described above in relation to the Company’s ability to meet its obligations and concluded that, without additional funding, the Company willnot have sufficient funds to meet its obligations withinone year from the date the Condensed Consolidated Financial Statements were issued. While management will look to continue funding operations by increased sales volumes and raising additional capital from sources such as sales of its debt or equity securities or loans to meet operating cash requirements, there isno assurance that management’s plans will be successful.

Management continues to monitor the immediate and future cash flows needs of the company in a variety of ways which include forecasted net cash flows from operations, capital expenditure control, new inventory orders, debt modifications, increases in sales outreach, streamlining and controlling general and administrative costs, competitive industry pricing, sale of equities, debt conversions, new product or services offerings, and new business partnerships.

The accompanying Condensed Consolidated Financial Statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive cash flows adequate to support the Company’s cost structure.

NOTE3 – STOCKHOLDERS’** EQUITY**

Warrants to Purchase Common Stock of the Company

We use the Black-Scholes-Merton option pricing model (“Black-Scholes Model”) to determine the fair value of Warrants. The Black-Scholes Model requires the use of a number of assumptions including expected volatility of the stock price, risk-free interest rate, and expected term. The expected volatility is based on the historical volatility of the Company’s stock. The risk-free interest rate was based on U.S. Treasury yields commensurate with the expected term of the warrants. The expected term of the warrants was based on the contractual term and management’s expectations of exercise behavior.

A summary of our Warrants activity and related information follows:

Stock Options

The Company’s Stock Incentive Plans include the CareView Communications, Inc.’s2007 Stock Incentive Plan (“2007 Plan”),2009 Stock Incentive Plan (the*“2009* Plan”),2015 Stock Option Plan (the*“2015* Plan”),2016 Stock Option Plan (the*“2016* Plan”),2020 Stock Option Plan ( the*“2020* Plan”), and2024 Stock Option Plan (the*"2024* Plan"), pursuant to which 8,000,000,10,000,000,5,000,000,20,000,000,20,000,000, and 30,000,000 shares of Common Stock were reserved for issuance upon the exercise of options, respectively. The Stock Incentive Plans are designed to serve as an incentive for retaining our qualified and competent key employees, officers and directors, and certain consultants and advisors. The Stock Options vest over three years and have an exercise period often years from the date of issuance.

At* June 30, 2026,Plan Options to purchase 8,000,000 shares of our Common Stock have been issued with zero remaining outstanding under the2007* Plan, Plan Options to purchase 10,000,000 shares have been issued with zero remaining outstanding under the2009 Plan, Plan Options to purchase 5,000,000 shares have been issued with 2,697,499 remaining outstanding under the2015 Plan, Plan Options to purchase 20,000,000 shares have been issued with 19,615,945 remaining outstanding under the2016 Plan, Plan Options to purchase 20,000,000 shares have been issued with 19,401,333 remaining outstanding under the2020 Plan and Plan Options to purchase 23,820,391 shares have been issued with 23,767,058 remaining outstanding under the2024 Plan.

The valuation methodology used to determine the fair value Plan Options (the “Option(s)”) issued was the Black- Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the weighted average risk-free interest rate, and the weighted average expected term of the options. The fair value of stock options granted was estimated using the Black-Scholes option pricing model with the following weighted-average assumptions: expected volatility ranging from 290.5% to 294.3%, an expected term of 6 years, a risk-free interest rate of 3.92%, and an expected dividend yield of 0%. The underlying stock price at the grant date ranged from $0.02 to $0.06, and the exercise price ranged from $0.02 to $0.06 per share.

11

A summary of our stock option activity and related information follows:

During thethree andsix months ended* June 30, 2026and2025,* share-based compensation expense for options were $151,609 and $301,911 for2026, and $156,002 and $310,734 for2025, respectively. The estimate of forfeitures is to be recorded at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates. We havenot included an adjustment to our stock-based compensation expense based on the nominal amount of the historical forfeiture rate. We do, however, revise our stock-based compensation expense based on actual forfeitures during each reporting period.

At* June 30, 2026*, total unrecognized estimated compensation expense related to non-vested Options granted prior to that date was approximately $412,590, which is expected to be recognized over a weighted-average period of 0.7 years. No tax benefit was realized due to a continued pattern of operating losses.

NOTE4 – OTHER CURRENT ASSETS

Other current assets consist of the following:

NOTE5 – INVENTORY

Inventory is valued at the lower of cost, determined on afirst-in,first-out (FIFO), or net realizable value. Inventory items are analyzed to determine cost and net realizable value and appropriate valuation adjustments are then established.

Inventory consists of the following:

12

NOTE6 – PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

Depreciation expense for thethree andsix months ended* June 30, 2026and2025* was $13,843 and $28,992 for2026, and $24,640 and $53,874 for2025, respectively.

NOTE7 – INTANGIBLE AND OTHER ASSETS, NET

Intangible assets consist of the following:

Amortization expense for thethree andsix months ended* June 30, 2026and2025* was $9,034 and $18,509 for2026, and $17,993 and $28,533 for2025, respectively.

13

Other assets consist of the following:

NOTE8 – OTHER CURRENT LIABILITIES

Other current liabilities consist of the following:

14

NOTE9 – AGREEMENT WITH PDL BIOPHARMA, INC.

On* June 26, 2015,*we entered into a Credit Agreement (as subsequently amended) with PDL BioPharma, Inc. (“PDL”), as administrative agent and lender (“the Lender”) (the “PDL Credit Agreement”).

On* December 11, 2024 (the “Effective Date”), the Company, the Borrower, the Lender, Steven G. Johnson, President and Chief Executive Officer of the Company, and Dr. James R. Higgins, a director of the Company, entered into a Ninth Amendment to Credit Agreement (the “Ninth Credit Agreement Amendment”), pursuant to which the parties agreed to amend the Credit Agreement to (i) provide that the Maturity Date shall be extended to March 31, 2025.*

On* March 21, 2025 (the “Effective Date”), the Company, the Borrower, the Lender, Steven G. Johnson, President and Chief Executive Officer of the Company, and Dr. James R. Higgins, a director of the Company, entered into a Tenth Amendment to Credit Agreement (the “Tenth Credit Agreement Amendment”), pursuant to which the parties agreed to amend the Credit Agreement to (i) provide that the Maturity Date shall be extended to June 30, 2025.*

On* June 30, 2025 (the “Effective Date”), the Company, the Borrower, the Lender, Steven G. Johnson, President and Chief Executive Officer of the Company, and Dr. James R. Higgins, a director of the Company, entered into an Eleventh Amendment to Credit Agreement (the “Eleventh Credit Agreement Amendment”), pursuant to which the parties agreed to amend the Credit Agreement to (i) provide that the Maturity Date shall be extended to September 30, 2025.*

On* September 30, 2025 (the “Effective Date”), the Company, the Borrower, the Lender, Steven G. Johnson, President and Chief Executive Officer of the Company, and Dr. James R. Higgins, a director of the Company, entered into an Twelfth Amendment to Credit Agreement (the “Twelfth Credit Agreement Amendment”), pursuant to which the parties agreed to amend the Credit Agreement to (i) provide that the Maturity Date shall be extended to December 31, 2025.*

On* December 31, 2025 (the “Effective Date”), the Company, the Borrower, the Lender, Steven G. Johnson, President and Chief Executive Officer of the Company, and Dr. James R. Higgins, a director of the Company, entered into a Thirteenth Amendment to Credit Agreement (the “Thirteenth Amendment to Credit Agreement”), pursuant to which the parties agreed to amend the Credit Agreement to (i) provide that the Maturity Date shall be extended to March 31, 2026.*

On* March 30, 2026 (the “Effective Date”), the Company, the Borrower, the Lender, Steven G. Johnson, President and Chief Executive Officer of the Company, and Dr. James R. Higgins, a director of the Company, entered into a Fourteenth Amendment to Credit Agreement (the “Fourteenth Credit Agreement Amendment”), pursuant to which the parties agreed to amend the Credit Agreement to (i) provide that the Maturity Date shall be extended to June**30,* 2026.

On* June 30, 2026 (the “Effective Date”), the Company, the Borrower, the Lender, Steven G. Johnson, President and Chief Executive Officer of the Company, and Dr. James R. Higgins, a director of the Company, entered into a Fifteenth Amendment to Credit Agreement (the “Fifteenth Credit Agreement Amendment”), pursuant to which the parties agreed to amend the Credit Agreement to (i) provide that the Maturity Date shall be extended to September30,* 2026. The note payable balance of $20,700,000 ($700,000 is due to related parties) as of* June30,* 2026, remains unchanged from prior periods. The associated interest continues to accrue on a straight-line monthly basis.

Accounting Treatment

On* June**30,* 2026 the Company entered into the Fifteenth Credit Agreement (as detailed above). Under ASC470-60-55-10, a concession is deemed to have been granted, and the agreement is to be accounted for as a troubled debt restructuring by debtors (TDR). The Company didnot have any debt restructuring costs and legal costs were expensed, as appropriate.

NOTE10 – LEASE

Under ASC Topic842, Leases (“ASC842”), operating lease expense is generally recognized evenly over the term of the lease. The Company has an operating lease primarily consisting of office space with a remaining lease term of 54 months.

On* May 8, 2025we entered into the Fifth Amendment to Commercial Lease Agreement, extending the term of the Lease until December 31, 2030 ("New Expiration Date"). We have concluded the Fifth Amendment to Commercial Lease Agreement qualifies as a lease modification (renewal) under ASC842.* As a result of the modification, The Company has remeasured the lease liability and right-of-use (ROU) asset as of the effective date of the amendment. The Company’s weighted average remaining lease term is approximately 4.5 years, and the weighted average discount rate applied in the calculation of the lease liability was approximately 12.5%.

The Company has further concluded that the Lease Extension hasno effects on the classification of the Lease, which continues as an operating lease. Rent expense for thesix months ended* June 30, 2026and2025* totaled $156,699 and $144,140, respectively.

15

Undiscounted Cash Flows

Future lease payments included in the measurement of operating lease liability on the Condensed Consolidated Balance Sheets as of* June 30, 2026*, for the followingfive fiscal years and thereafter as follows:

NOTE11 – SEGMENT REPORTING

The Company hasone reportable segment as it only reports operating results on an aggregated basis to the Chief Executive Officer who serves as the Chief Operating Decision Maker (CODM). The Company derives revenue and manages the business activities on a consolidated basis. For thethree andsix months ended* June30,2026, and*2025*,* all revenues from the Company’s external customers were derived, and all long-lived assets were located, in the United States.

The CODM is regularly provided with financial information, including revenue and expenses, in a format consistent with the Company’s Condensed Consolidated Statements of Operations. The CODM regularly reviews reported consolidated revenues, significant expenses, and consolidated net loss. The CODM considers these measures, as well as other factors, such as an assessment of a new product’s future market potential, when determining how to allocate company-wide resources. The CODM doesnot review assets at a different level or category than those disclosed in the Condensed Consolidated Balance Sheets.

Significant expenses are amounts that are regularly provided to the CODM and included in consolidated net income (loss), the Company’s primary measure of its single segment’s profit or loss.

Segment financial information used by the CODM to assess segment performance and make decisions about resource allocation was as follows:

NOTE12 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events through* August 12, 2026*.

16